鞘内注射NIS-lncRNA反义寡核苷酸对神经创伤、化疗或糖尿病所致神经病理性疼痛的作用
该研究采用FDA批准的反义寡核苷酸策略,在小鼠神经病理性疼痛模型中鞘内注射NIS-lncRNA ASOs,评估其对机械性异常性疼痛、热痛觉过敏、冷痛觉过敏及持续伤害性反应的影响。结果显示ASOs可减轻CCI、脊神经结扎及紫杉醇或链脲佐菌素诱导的痛觉过敏,并抑制DRG中NIS-lncRNA和CCL2表达及脊髓神经元和星形胶质细胞过度活跃,且未观察到细胞毒性。
要点
- 鞘内NIS-lncRNA ASOs减轻CCI诱导的机械性异常性疼痛、热痛觉过敏和冷痛觉过敏。
- ASOs抑制DRG中NIS-lncRNA和CCL2表达及脊髓神经元和星形胶质细胞过度活跃。
- ASOs在脊神经结扎及紫杉醇或链脲佐菌素诱导的神经病理性疼痛模型中同样有效。
核心结论
- 鞘内注射NIS-lncRNA反义寡核苷酸可减轻神经创伤、化疗或糖尿病诱导的神经病理性疼痛,并抑制DRG中NIS-lncRNA和CCL2表达及脊髓神经元和星形胶质细胞过度活跃。
- NIS-lncRNA反义寡核苷酸未产生细胞毒性,提示其潜在的临床应用价值。
研究设计与样本
- 研究采用FDA批准的反义寡核苷酸策略,在小鼠神经病理性疼痛模型中鞘内注射NIS-lncRNA ASOs。
- 模型包括慢性坐骨神经压迫损伤(CCI)、第四腰(L4)脊神经结扎、腹腔注射紫杉醇或链脲佐菌素。
- 在CCI后第7天或第14天评估ASOs对DRG中NIS-lncRNA和CCL2表达及痛觉过敏的影响。
主要发现
- 鞘内NIS-lncRNA ASOs减轻CCI诱导的机械性异常性疼痛、热痛觉过敏、冷痛觉过敏和持续伤害性反应,不改变基础或急性伤害性反应及运动功能。
- ASOs阻断CCI诱导的同侧L3和L4 DRG中NIS-lncRNA和CCL2增加及同侧L3和L4脊髓背角神经元和星形胶质细胞过度活跃。
- 在脊神经结扎或腹腔注射紫杉醇或链脲佐菌素的小鼠中,ASOs处理也产生类似结果。
- ASOs处理小鼠的DRG和脊髓形态结构正常,未见细胞丢失。
临床怎么用
- 鞘内注射NIS-lncRNA反义寡核苷酸可能成为神经创伤、化疗或糖尿病所致神经病理性疼痛的潜在治疗策略。
- 该策略利用FDA批准的反义寡核苷酸技术,具有临床转化潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blocking increased expression of nerve injury-specific long non-coding RNA (NIS-lncRNA) in injured dorsal root ganglia (DRG) through DRG microinjection of NIS-lncRNA small hairpin interfering RNA or generation of NIS-lncRNA knockdown mice mitigates neuropathic pain. However, these strategies are impractical in the clinic. This study employed a Food and Drug Administration (FDA)-approved antisense oligonucleotides strategy to examine the effect of NIS-lncRNA ASOs on neuropathic pain. METHODS: Effects of intrathecal injection of NIS-lncRNA antisense oligonucleotides on day 7 or 14 after chronic constriction injury (CCI) of the sciatic nerve, fourth lumbar (L4) spinal nerve ligation, or intraperitoneal injection of paclitaxel or streptozotocin on the expression of DRG NIS-lncRNA and C-C chemokine ligand 2 (CCL2, an NIS-lncRNA downstream target) and nociceptive hypersensitivity were examined. We also assessed whether NIS-lncRNA antisense oligonucleotides produced cellular toxicity. RESULTS: Intrathecal NIS-lncRNA antisense oligonucleotides attenuated CCI-induced mechanical allodynia, heat hyperalgesia, cold hyperalgesia, and ongoing nociceptive responses, without changing basal or acute nociceptive responses and locomotor function. Intrathecal NIS-lncRNA antisense oligonucleotides also blocked CCI-induced increases in NIS-lncRNA and CCL2 in the ipsilateral L3 and L4 DRG and hyperactivities of neurones and astrocytes in the ipsilateral L3 and L4 spinal cord dorsal horn. Similar results were found in antisense oligonucleotides-treated mice after spinal nerve ligation or intraperitoneal injection of paclitaxel or streptozotocin. Normal morphologic structure and no cell loss were observed in the DRG and spinal cord of antisense oligonucleotides-treated mice. CONCLUSION: These findings further validate the role of NIS-lncRNA in trauma-, chemotherapy-, or diabetes-induced neuropathic pain and demonstrate potential clinical application of NIS-lncRNA antisense oligonucleotides for neuropathic pain management.
引用
- Wen CH, Berkman T, Li X, et al. Effect of intrathecal NIS-lncRNA antisense oligonucleotides on neuropathic pain caused by nerve trauma, chemotherapy, or diabetes mellitus. Br J Anaesth. 2022. PMID: 36460518. doi:10.1016/j.bja.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。